Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Celgene, Agios Eye Cancer Metabolism

by Lisa M. Jarvis
April 26, 2010 | A version of this story appeared in Volume 88, Issue 17

Celgene and Agios Pharmaceuticals have established a broad collaboration to discover and develop drugs targeting cancer metabolism. Celgene will pay $130 million in exchange for a stake in Agios and, for a period of time, exclusive rights to develop any drug candidates coming out of Agios’ pipeline. Agios is focused on depriving cancer cells of their energy source by using small molecules to control critical metabolic enzymes. Those targets include isocitrate dehydrogenase, shown to play a role in cancer formation, and pyruvate kinase M2, an enzyme involved in glucose metabolism.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.